Principle of Superposition in Multiple Drug Dosing

1. Definition

• The principle of superposition states that the plasma drug concentration at any time during multiple dosing is simply the arithmetic sum of the concentrations contributed by each individual dose, as if each dose had been given alone and independently.
• It rests on the assumption that the pharmacokinetics of a drug are linear - meaning that processes such as absorption, distribution, and elimination follow first-order kinetics and are not altered or saturated by repeated dosing.
• Stated simply: early doses do not change the pharmacokinetic parameters (clearance, volume of distribution, half-life) of subsequent doses.

2. Core Assumptions

• Linear pharmacokinetics: The rate of elimination is proportional to drug concentration (first-order), so doubling the dose doubles the concentration.
• Dose-independent parameters: Clearance (CL) and volume of distribution (Vd) are constant regardless of dose size or number of doses administered.
• No enzyme induction/inhibition or receptor saturation alters drug behaviour over time.
• If any of these conditions are violated (e.g., non-linear Michaelis-Menten kinetics, as with phenytoin or alcohol), the superposition principle does not apply.

3. Mathematical Basis

• For a one-compartment model with IV bolus dosing, the concentration after a single dose D at time t is:
  C(t) = (D/Vd) × e^(-k·t)
  where k = elimination rate constant.
• When a second dose is given at time τ (the dosing interval), the total concentration is simply:
  C(total) = C(from dose 1) + C(from dose 2)
• For n doses at equal interval τ, the total concentration at any time is the sum of all residual concentrations from each previous dose. This is the formal expression of superposition.

4. Drug Accumulation

• Because drugs are eliminated exponentially, some drug from a previous dose always remains when the next dose is administered (unless the dosing interval far exceeds 5 half-lives).
• Each new dose adds to this residual, causing progressive accumulation - exactly as predicted by superposition.
• The accumulation factor quantifies this:

  Accumulation factor = 1 / (1 - e^(-0.693 × τ/t½))

  For a drug dosed every half-life, the accumulation factor = 2. This means peak steady-state concentrations will be 2× the peak after the first dose.
• Importantly: accumulation is predictable using superposition, because the contribution of each dose can be calculated and summed.
  - Katzung's Basic and Clinical Pharmacology, 16th Edition, Drug Accumulation

5. Approach to Steady State

• As doses accumulate, plasma concentrations oscillate between a Cmax (peak) and Cmin (trough) within each dosing interval.
• The mean concentration rises progressively until the rate of drug elimination equals the rate of administration - this is the steady state (Css).
• Steady state is reached after approximately 4-5 half-lives, regardless of dose size or dosing frequency.
  • 50% of Css → after 1 half-life
  • 75% of Css → after 2 half-lives
  • 90% of Css → after 3.3 half-lives
  • ~100% of Css → after 4-5 half-lives
  - Lippincott Illustrated Reviews: Pharmacology

6. Effect of Dose Size and Frequency

• Doubling the dose doubles the steady-state concentration (Css ∝ dose), without altering the time to reach steady state. This is a direct consequence of linearity.
• Increasing dosing frequency (e.g., from once to twice daily) reduces peak-to-trough fluctuation but does not change the average Css or the time to reach it.
• Continuous IV infusion (equivalent to infinitely frequent small doses) produces a smooth, fluctuation-free rise to steady state - the theoretical ideal of superposition with zero oscillation.

7. Loading Dose and Dose Adjustment

• Loading dose: Because steady state normally takes 4-5 half-lives, a large initial (loading) dose can rapidly achieve therapeutic concentrations - but it does not change the ultimate steady state or the time course of accumulation for subsequent doses.
• Dose reduction or discontinuation: After any change in dosing at steady state, a new steady state is reached again in ~5 half-lives - fully predictable by superposition.

8. Clinical Significance

Summary

Conversion of Intravenous (IV) to Per Oral (PO) Dosing

Why Convert IV to Oral?

• IV therapy is used when rapid, reliable drug delivery is required - but it carries risks (catheter infections, thrombophlebitis, medication errors) and limits patient mobility.
• Once a patient is clinically stable with a functioning GI tract, converting to oral dosing is safer, cheaper, and more comfortable.
• The pharmacokinetic challenge is that IV bioavailability = 100%, while oral bioavailability (F) is often < 100% due to incomplete absorption and/or first-pass metabolism.

Prerequisites Before Conversion

1. Clinical stability - afebrile trend, improving vitals
2. Functioning GI tract - able to swallow, no ileus, no severe vomiting/diarrhoea
3. Oral formulation available for the same drug (or a suitable therapeutic equivalent)
4. No contraindication to enteral feeding or oral absorption (e.g., short bowel, malabsorption syndromes)

Method 1: Same-Dose Conversion (Direct Switch)

Principle

• Used when the oral bioavailability of a drug is high (≥ 80-90%).
• The oral dose equals the IV dose because systemic exposure is essentially the same by both routes.

Formula

Dose(oral) = Dose(IV)

Examples

• Fluoroquinolones are the classic example - ideal for direct switch due to near-complete oral bioavailability.

Method 2: Dose-Equivalent Conversion (Dose Adjustment for Bioavailability)

Principle

• Used when oral bioavailability is moderate (30-80%).
• The oral dose must be increased relative to the IV dose to maintain equivalent systemic exposure (same AUC).
• The AUC under both routes must be equal:

AUC(oral) = AUC(IV)

Formula

Concept: Salt Factor (S)

• If the oral formulation is a different salt or ester of the same drug, an additional correction factor S must be applied.
• Example: Aminophylline (IV) contains 85% theophylline by weight, so S = 0.85.

Worked Example (Aminophylline → Theophylline)

• A patient receives aminophylline IV infusion at 34 mg/hr.
• Convert to oral theophylline (F = 1.0, S = 0.85):
  • Daily IV dose = 34 × 24 = 816 mg aminophylline/day
  • Equivalent theophylline = 816 × 0.85 = 693.6 mg theophylline/day
  • Prescribe: theophylline 350 mg PO q12h (sustained-release preferred to minimise peak-trough fluctuation)

Examples

• Katzung's Basic and Clinical Pharmacology, 16th Edition: "A major consequence of the low bioavailability of propranolol is that oral administration of the drug leads to much lower drug concentrations than are achieved after intravenous injection of the same dose."

Why oral bioavailability is < 100%: Two mechanisms

• Drug too hydrophilic (e.g., atenolol) or too lipophilic (e.g., acyclovir) to cross the gut wall
• Degradation in gastric acid (e.g., benzylpenicillin)

• Drugs with high ER (morphine, lidocaine, propranolol, isoniazid) undergo extensive first-pass loss, drastically reducing oral F.
• Lidocaine cannot be given orally at all because first-pass generates toxic metabolites.

Method 3: Therapeutic Substitution

Principle

• Used when no oral formulation of the IV drug exists, or the oral formulation is impractical.
• A pharmacologically equivalent drug from the same class with adequate oral bioavailability is substituted.
• Requires clinical judgement about equivalent efficacy and safety - not purely a pharmacokinetic calculation.

Examples

• This method is commonly used in antimicrobial stewardship programmes to reduce IV catheter days and hospital costs.

Method 4: AUC-Based / Pharmacokinetic Modeling Approach

Principle

• For drugs with narrow therapeutic indices (e.g., digoxin, theophylline, cyclosporin, tacrolimus, vancomycin), conversion must be guided by therapeutic drug monitoring (TDM).
• The goal is to match the steady-state AUC rather than just the dose.

Steps

1. Calculate target steady-state concentration (Css) from the IV regimen.
2. Calculate the required oral dose rate using: $$\text{Dose rate}{\text{oral}} = C{ss} \times CL / F$$
3. After switching, measure plasma levels at appropriate time points (usually after 4-5 half-lives of the new regimen).
4. Adjust oral dose based on measured levels.

Clinical Relevance

• Amiodarone: oral bioavailability ~30%; IV-to-oral loading protocols require weeks due to the drug's enormous volume of distribution and long half-life.
  • Goodman & Gilman's: "This incomplete bioavailability is important in calculating equivalent dosing regimens when converting from intravenous to oral therapy."
• Digoxin: oral F varies (60-80%); TDM required after switch.
• Cyclosporin/Tacrolimus: extended-release oral formulations have slightly higher bioavailability than standard - dose reduction may be needed.
  • Tietz Textbook of Laboratory Medicine: "Extended-release formulations afford delayed maximal concentrations with improved bioavailability leading to a slight reduction in dose to achieve equivalent AUC."

Summary Table

Key Formula to Remember